Candel Therapeutics, Inc. (CADL) Key Metrics
CADL valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $626.7M
- Enterprise value
- $711.8M
- P/E (TTM)
- —
- Forward P/E
- 43.5
- PEG ratio
- —
- Price / sales
- 436.4
- Price / book
- 6.8 10-yr median 3.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.31
CADL key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCADL valuation Price multiples at each fiscal year-end price.
CADL returns How much profit the business earns on the capital it uses.
CADL per-share figures Results divided by the shares outstanding at year-end.
CADL financial health Debt, liquidity and how easily interest is covered.
CADL efficiency & capital use Working capital cycle and where the cash goes.
CADL valuation history
CADL returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CADL debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CADL cash returned to shareholders
CADL price vs earnings per share
CADL key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $299.2M | $274.9M | $42.5M | $51.6M | $147.6M | — | — |
| Enterprise value | $181.4M | $185.8M | $29.9M | $4.3M | $65.5M | — | — |
| Price / sales | — | — | — | 412.8 | — | — | — |
| Price / book | 5.8 | 4.1 | 3.3 | 1.1 | 2.3 | — | — |
| EV / sales | — | — | 964.0 | 34.7 | 524.0 | — | — |
| Earnings yield | −12.8% | −20.1% | −89.2% | −36.4% | −24.5% | — | — |
| Free cash flow yield | −13.0% | −9.8% | −81.6% | −63.4% | −16.3% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.3% | — | 0.0% | — | — |
| Share price at fiscal year-end | $5.65 | $8.68 | $1.47 | $1.79 | $7.82 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 | $0.01 | $0.01 |
| Earnings per share | −$0.72 | −$1.74 | −$1.31 | −$0.65 | −$1.91 | −$0.94 | −$0.44 |
| Operating cash flow per share | −$0.72 | −$0.85 | −$1.18 | −$1.09 | −$1.18 | −$0.48 | −$0.28 |
| Free cash flow per share | −$0.73 | −$0.85 | −$1.20 | −$1.14 | −$1.27 | −$0.56 | −$0.29 |
| Cash per share | $2.26 | $3.24 | $1.22 | $2.43 | $4.38 | $1.87 | $2.41 |
| Book value per share | $0.98 | $2.09 | $0.44 | $1.66 | $3.40 | −$1.26 | −$0.43 |
| Tangible book value per share | $0.98 | $2.09 | $0.44 | $1.66 | $3.40 | −$1.26 | −$0.43 |
| Capex per share | $0.01 | $0.00 | $0.02 | $0.04 | $0.10 | $0.08 | $0.01 |
| Debt per share | $0.04 | $0.43 | $0.79 | $0.79 | $0.03 | $0.05 | $0.02 |
| Shares outstanding | 53.0M | 31.7M | 28.9M | 28.8M | 18.9M | 18.7M | 18.7M |
| Change in shares outstanding | +67.2% | +9.5% | +0.4% | +52.7% | +0.8% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −64.6% | −139.6% | −125.5% | −33.6% | −178.1% | — | — |
| Return on assets (ROA) | −32.9% | −74.5% | −63.4% | −22.4% | −56.7% | −42.0% | −18.0% |
| Return on tangible assets | −30.5% | −51.6% | −92.1% | −23.9% | −40.5% | −46.2% | −18.0% |
| Financial health | |||||||
| Total debt | $1.9M | $13.5M | $22.8M | $22.8M | $560,000 | $946,000 | $420,000 |
| Cash & short-term investments | $119.7M | $102.7M | $35.4M | $70.1M | $82.6M | $35.1M | $45.1M |
| Net debt | −$117.8M | −$89.2M | −$12.7M | −$47.3M | −$82.1M | −$34.1M | −$44.6M |
| Debt / equity | 0.04 | 0.20 | 1.79 | 0.48 | 0.01 | — | — |
| Debt / assets | 0.02 | 0.13 | 0.55 | 0.29 | 0.01 | 0.02 | 0.01 |
| Current ratio | 13.31 | 2.77 | 2.59 | 12.81 | 15.84 | 7.46 | 32.06 |
| Quick ratio | 13.31 | 2.77 | 2.59 | 12.81 | 15.84 | 7.46 | 32.06 |
| Interest coverage | -22.8 | -16.0 | -14.8 | -20.3 | -485.4 | -124.4 | -8.4 |
| Working capital | $110.7M | $66.3M | $22.6M | $66.3M | $79.6M | $30.4M | $43.8M |
| Invested capital | −$65.9M | −$22.9M | $94,000 | $456,000 | −$17.9M | −$57.7M | −$52.7M |
| Tangible asset value | $51.9M | $66.3M | $12.7M | $47.7M | $64.1M | −$23.6M | −$8.0M |
| Net current asset value | $46.5M | $63.3M | $8.3M | $41.1M | $59.9M | −$26.7M | −$8.7M |
| Graham net-net per share | $0.88 | $1.96 | $0.24 | $1.36 | $3.05 | −$1.43 | −$0.47 |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | $121,000 | — | $0 | — | — |
| Capex / revenue | — | — | 1,474.2% | 1,037.6% | 1,468.0% | 1,180.8% | 127.2% |
| Capex / depreciation | 0.69 | 0.02 | 0.48 | 1.67 | 7.91 | 16.22 | 3.70 |
| Stock-based compensation / revenue | — | — | 9,971.0% | 1,845.6% | 2,370.4% | 1,685.6% | 320.0% |
| R&D / revenue | — | — | 79,051.6% | 16,629.6% | 12,142.4% | 7,003.2% | 5,285.6% |
| SG&A / revenue | — | — | 47,006.5% | 11,248.0% | 8,538.4% | 4,144.8% | 2,044.0% |
| Efficiency | |||||||
| Days payables outstanding | 295.0 | 121.5 | 6.1 | 364.3 | 1,975.2 | — | 12.0 |
| Payables turnover | 1.24 | 3.00 | 59.80 | 1.00 | 0.18 | 0.00 | 30.31 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $683,000 | $329,500 | $401,000 | $985,000 | $1.3M | $569,500 | $218,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CADL's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CADL valuation and financial ratios
Candel Therapeutics earned a return on equity of −64.6% in fiscal 2025. It ended the year with $1.9 million of debt and $119.7 million in cash and short-term investments, a net cash position of $117.8 million. The share count rose 183.0% from 18.7M to 53.0M over 6 years.
See the CADL income statement, the CADL chart for price history, or the CADL stock overview for the latest quote and news.
CADL key metrics FAQ
What is Candel Therapeutics's return on equity?
Candel Therapeutics's return on equity (ROE) was −64.6% in fiscal 2025: net income of -$38.2 million on average shareholders' equity of $59.1 million.
How much debt does Candel Therapeutics have?
Candel Therapeutics had total debt of $1.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.04 and more cash than debt.
What is Candel Therapeutics's free cash flow yield?
Candel Therapeutics generated -$38.9 million of free cash flow in fiscal 2025, a free cash flow yield of −13.0% on its market value at year-end ($299.2 million).
What is Candel Therapeutics's current ratio?
Candel Therapeutics's current ratio was 13.31 at the end of fiscal 2025: current assets were 13.31 times current liabilities.